Folium Biosciences Names Nutralliance a Preferred U.S. Distributor of Company’s Hemp-Derived Non-Psychoactive Cannabinoid (CBD) Products
Hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences and premium-ingredient sales and marketing company Nutralliance have entered a distribution partnership that grants Nutralliance the right to distribute Folium’s industry-leading 0.0% THC broad spectrum CBD oil products in the United States, and establishes Folium as Nutralliance’s exclusive CBD supplier.
by Q2Mark 
Folium Biosciences Completes Construction of One of the World’s Largest Cannabinoid Extraction and Purification Facilities in Pueblo West, CO
Folium Biosciences has completed buildout and received a Certificate of Occupancy for the world’s largest cannabinoid extraction and purification facility, located in Pueblo West, Colo.
The new 110,000-square-foot Pueblo West facility will produce up to 22,000 kg of 0.0% THC broad spectrum CBD oil each month. To satisfy accelerating demand from CBD product manufacturers worldwide, the plant has dedicated production lines to meet CBD regulatory requirements in the US, EU, Japan, and South Korea, among other countries.
FDA registered and state-of-the-art, the new Folium facility is purpose-built for extraction, purification and formulation of cannabinoids and terpenes. The plant will utilize supercritical carbon dioxide (sCO2) extraction technology exclusively to produce phytocannabinoid-rich 0.0% THC broad spectrum CBD oil, adhering to a continuous process from decarboxylation to extraction that allows for a revolutionary inline terpene capture system.
by Q2Mark 
Folium Biosciences’ General Counsel, Craig Brand Presents Closing Remarks at FDA Hearings on CBD
The FDA is taking its first step in setting new regulations for cannabis Friday, holding a public hearing to dive into what its regulatory strategy should address. FDA Commissioner Scott Gottlieb has expressed concerns about companies making claims of the health benefits of CBD. But he also recognizes regulations are needed to provide clarity for companies that want to market cannabis products. Potential safety issues are expected to be a major topic at the hearing. (Fox Business)
by Q2Mark